Eli Lilly (LLY) shares rose Thursday after the drugmaker's adjusted profit came in above estimates ... Sales of the company's ...

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...

The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Eli Lilly has today forecast annual profit largely above Wall Street estimates, providing some relief to investors after ...

Analysts had expected profit of $4.52 billion ... the Danish company behind weight-loss drugs Ozempic and Wegovy, topped estimates in its fourth-quarter report. Eli Lilly shares were up roughly ...

On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...